Forex
World
Market
Business
Cryptocurrency
Commodities
MAP
Publish for free
Business
financetom
/
Business
/
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
Forex
Stocks Market
Commodities
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
Apr 30, 2026 8:29 AM
11:10 AM EDT, 04/30/2026 (MT Newswires) --
Price: 37.75, Change: +1.67, Percent Change: +4.63
Previous page:
US telecom agency votes to expand tech crackdown on China
Next page:
Why Is Crocs Stock Falling Thursday?
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Release time ⇩
Release time ⇧
Like count ⇩
Show More Comments
Related Articles >
US telecom agency votes to expand tech crackdown on China
Apr 30, 2026
WASHINGTON, April 30 (Reuters) - The Federal Communications Commission on Thursday voted to advance a proposal to bar all Chinese labs from testing electronic devices such as smartphones, cameras and computers for use in the United States. The FCC is also set take an initial vote on Thursday on a separate proposal to bar three major Chinese telecom companies from...
Why Is Crocs Stock Falling Thursday?
Apr 30, 2026
Crocs, Inc. ( CROX ) shares traded lower Thursday after the footwear maker reported a mixed first-quarter performance, as strength in its core brand and raised guidance failed to offset weakness in HEYDUDE and margin compression. Earnings Beat Expectations, But Revenue Declines The company posted adjusted earnings of $2.99 per share, topping the analyst consensus estimate of $2.77. Revenue declined...
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
Apr 30, 2026
11:10 AM EDT, 04/30/2026 (MT Newswires) -- Price: 37.75, Change: +1.67, Percent Change: +4.63 ...
Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout
Apr 30, 2026
11:08 AM EDT, 04/30/2026 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said the US Food and Drug Administration agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma under the agency's Oncology Center of Excellence Real-Time Oncology Review program. The phase 2/3 trial of darovasertib in combination with...
About
Terms and Conditions
Privacy policy
Cookie Settings
Contact Us
Services
Login
register
financetom
Market
Personal Finance
Business
Economy
Cryptocurrency
MAP
Links
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
Copyright 2023-2026 -
www.financetom.com
All Rights Reserved
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
MAP